Myogen Release: Darusentan Data To Be Presented At ISH 2006 • Fukuoka, Japan

Published: Oct 18, 2006

DENVER--(BUSINESS WIRE)--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of darusentan on resistant hypertension (RHTN) has been selected for presentation at the International Society of Hypertension (ISH) to be held Oct. 15-19, 2006, in Fukuoka, Japan.

Back to news